However, the absence of correlation between EZH2 mutational profile or LymphGen classification subgroups (EZB vs. other) on the one hand and CMR on the other suggests that TAZ has a broader mechanism of action and/or that a distinct molecular alteration can lead to similar functional consequences as the EZH2 gain-of-function mutation, as reported in follicular lymphoma.31 The gene discussed is EZH2; the disease is follicular lymphoma.